Antiretroviral Therapy

SAN FRANCISCO — Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, baseline suppressive therapies among adults with HIV.

SAN FRANCISCO — HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled from decades of studies, researchers found.

Millions of children in Africa rely on funding from the United States for HIV care or testing — support that was threatened last month when President Donald J. Trump froze foreign aid spending after taking office.

Adults in Tanzania living with HIV and taking tenofovir have a higher rate of chronic kidney disease vs. those without the viral infection, according to a prospective cohort study.

For organ transplant recipients with HIV, kidneys from deceased donors with HIV are noninferior those from donors without HIV, according to data from a U.S. multicenter observational trial.

HHS this week announced that it will allocate more than $1.4 billion in funding through the Ryan White HIV/AIDS Program to help people with HIV who have low incomes receive medication and care.

People with virally suppressed HIV who are hospitalized with community acquired pneumonia do not have a higher mortality risk than people without HIV, according to a study.

In June, Gilead Sciences announced that its investigational antiretroviral drug lenacapavir prevented 100% of new HIV infections during a phase 3 trial conducted among cisgender women in Africa.

Patients with HIV who undergo immediate antiretroviral therapy may not experience significant differences in chronic kidney disease outcomes compared with patients who defer treatment.